Company news

Mesoblast Limited news in 2016

Mesoblast Limited's news releases, calls and decks from 2016, newest first.

View company

Half-Year Results & Strategic Update on Product Development

March 30, 2016

Response to ASX price query

March 30, 2016

Positive Disc Repair Results Using Mesoblast Stem Cells

March 30, 2016

New Japanese Regenerative Medicine Legislation

March 30, 2016

MSBs Registration Plans for GVHD Cell Product in Japan

March 30, 2016

MSB Receives $4.3M Pipeline Funds from Australian Government

March 30, 2016

MPCs Strengthen Cardiac Function in End-Stage Heart Failure

March 30, 2016

MPCs Induce Functional Recovery in Ischemic Stroke Model

March 30, 2016

Mesoblast Reports Positive Type 2 Diabetes Trial Results

March 30, 2016

Mesoblast provides update on clinical programs of prochymal

March 30, 2016

Mesoblast, Intrexon and Ziopharm to Target Cancers

March 30, 2016

Mesoblast Acquires Osiris Cultured Stem Cell Business

March 30, 2016

Key European Patent Granted for Mesoblasts MPCs

March 30, 2016

MSB & NIH Agree 120 Patient Trial In End-Stage Heart Failure

March 30, 2016

MSB Accelerates Plans for Commercial Manufacturing Operation

March 30, 2016

Mesoblast Receives $5.05m for Stem Cell Pipeline Development

March 30, 2016

Circulation Publishes Improved Outcomes with Mesoblast Cells

March 30, 2016

Key US Patent Granted For Treatment Of Rheumatoid Arthritis

March 23, 2016

GVHD Product Launched In Japan

February 24, 2016

Increased Survival Using MSB Cells In Children With aGVHD

February 21, 2016

Half Yearly Report and Accounts (including Appendix 4D)

February 16, 2016

MSB Therapy Shows Benefit In First Cohort Of RA Patients

February 15, 2016

Phase 3 Heart Failure Trial Size Substantially Reduced

February 11, 2016

US Govt Grants for Further Development of Stem Cell Products

February 10, 2016

USA FDA Clears Phase 2 Trial For Cervical Spinal Fusion

February 10, 2016

Type 2 Diabetes Trial Results Published In Diabetes Care

February 10, 2016

Strategic Update and Q1 Financial Results Presentation

February 10, 2016

Rheumatoid Arthritis New Major Clinical Target for MSB

February 10, 2016

Reversed Arterial Dysfunction And Inflammation in RA Model

February 10, 2016

Results Show Improved Survival in Children with GVHD

February 10, 2016

Response to ASX Price Query Letter

February 10, 2016

Quarterly Results Filed on Form 6-K with SEC

February 10, 2016

Positive Results Using Adult Stem Cells for Type 2 Diabetes

February 10, 2016

Positive Outcome From FDA Meeting For Diabetes Program

February 10, 2016

Positive interim results in phase 2 trial for disc repair

February 10, 2016

Positive EMA Meeting For Phase 3 Disc Repair Program

February 10, 2016

Positive Diabetic Nephropathy Trial Results

February 10, 2016

P3 trial initiated, positive 24 mth P2 results in back pain

February 10, 2016

MSB Unveils Path to Bring its Key Products to Market

February 10, 2016

MSB to Begin Phase 2 Trial of MPCs in Diabetic Nephropathy

February 10, 2016

MSBs Japan Licensee Receives Pricing For TEMCELL

February 10, 2016

MSB Partner JCR Receives Recommendation For Japan Approval

February 10, 2016

MSB Cell Therapy Shows Greatest Effect In Advanced CHF

February 10, 2016

Mesoblast Update on Valeant Proposal to Cephalon

February 10, 2016

Mesoblast To Acquire Angioblast Systems, 37M Capital Raising

February 10, 2016

Mesoblast Receives $5.8m From Aus Govt For R&D

February 10, 2016

Mesoblast Provides Strategic Update and Q1 Financial Results

February 10, 2016

Mesoblast Lists On Nasdaq

February 10, 2016

Mesoblast Enters into Agreements to Raise A$170million

February 10, 2016

Key US patent granted for treatment of degenerated discs

February 10, 2016

← Newer news releases · Older news releases →

Decks in 2016